Health Care Provider Practices and Perceptions of Biomarker Testing in US Veterans With Non-Small Cell Lung Cancer
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Pulmonologists’ Attitudes and Role in Precision Medicine Biomarker Testing for Non-Small Cell Lung CancerChest, 2024
- Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementationESMO Open, 2023
- Trends in Real-World Biomarker Testing and Overall Survival in US Patients with Advanced Non-Small-Cell Lung CancerFuture Oncology, 2022
- Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2022
- Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung CancerChest, 2021
- The evolving landscape of biomarker testing for non-small cell lung cancer in EuropeLung Cancer, 2021
- The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung CancerJournal of Thoracic Oncology, 2020
- The Effect of Advances in Lung-Cancer Treatment on Population MortalityNew England Journal of Medicine, 2020
- Race, Poverty, and Initial Implementation of Precision Medicine for Lung CancerJNCI: Journal of the National Cancer Institute, 2019
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyArchives of Pathology & Laboratory Medicine, 2018